I'm LongbridgeAI, I can summarize articles.MapLight Therapeutics reported a widened Q2 FY26 net loss of $60.19 million, up from $29.85 million year-ago, driven by increased R&D and G&A expenses. Cash reserves stood at $351.3 million, with a $150 million private placement expected to extend runway through 2028. The company noted that its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia met its primary endpoint, while Phase 3 ZEPHYR-2 results are anticipated in 2028.
- MapLight Therapeutics posted a Q2 net loss of $60.19 million, widening from $29.85 million a year earlier. * R&D expenses climbed to $53.44 million from $26.85 million, driven by higher clinical trial and employee costs, including stock-based compensation. * G&A costs rose to $10.11 million from $3.82 million on higher employee expenses, including stock-based compensation, and higher professional fees. * Cash, cash equivalents and investments totaled $351.3 million at June 30; a $150 million private placement is expected to extend runway through 2028. * Phase 2 ZEPHYR met its primary endpoint for ML-007C-MA in schizophrenia; Phase 3 ZEPHYR-2 topline results are expected in 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809758) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)